Accord Agrees Leuprolide Deal as Part of Differentiation Strategy

 
• By Aidan Fry

Accord is furthering its push into added-value medicines by entering into a licensing agreement for Foresee’s injectable suspension leuprolide injectable.

Darts
A global alliance with Foresee for ready-to-use formulation of leuprolide forms part of Accord Healthcare's differentiation strategy • Source: Shutterstock

More from Value Added Medicines

More from Products